-
Taxonomy & unit
-
us-gaap: shares
-
Description
-
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
-
Summary
-
Halozyme Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from 2015 to 2023.
- Halozyme Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending June 30, 2024 was 129M shares, a 3.24% decline year-over-year.
- Halozyme Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 134M shares, a 4.56% decline from 2022.
- Halozyme Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 141M shares, a 4.22% decline from 2021.
- Halozyme Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2021 was 147M shares, a 3.77% increase from 2020.
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Growth (%)